Peer-influenced content. Sources you trust. No registration required. This is HCN.
ASH Clinical News
The U.S. Food and Drug Administration (FDA) held a two-day public meeting to discuss managing the potential side effects of gene therapies following the death of a boy with a rare neuromuscular disease. High doses of gene therapies are known to cause liver damage, and recent studies have also found a potential long-term cancer risk in mice and dogs treated with gene therapies.
Hematology November 16th 2021
Medical Professionals Reference (MPR)
Findings: Primary outcomes included AMI, HF, stroke, and CVEs; 51 secondary and safety outcomes included angioedema, cough, syncope, and electrolyte abnormalities. ACE inhibitors were associated with a significantly increased risk of four secondary and safety outcomes compared with ARBs.Design: Multinational cohort study; Patients: ~2.3M ACE, ~674K ARB
Cardiology August 3rd 2021